MCID: PRS021
MIFTS: 51

Prostatic Adenoma

Categories: Cancer diseases, Reproductive diseases

Aliases & Classifications for Prostatic Adenoma

MalaCards integrated aliases for Prostatic Adenoma:

Name: Prostatic Adenoma 12 54 15 71
Prostatic Hyperplasia 43 71
Benign Prostatic Hyperplasia 71
Benign Adenoma of Prostate 12
Adenoma of Prostate 12
Adenoma - Prostate 12
Prostate Adenoma 12

Classifications:



External Ids:

Disease Ontology 12 DOID:2883
MeSH 43 D011470
NCIt 49 C4795
SNOMED-CT 67 21173002
UMLS 71 C0520477 C1704272 C2937421

Summaries for Prostatic Adenoma

Disease Ontology : 12 A male reproductive organ benign neoplasm that derives from glandular epithelial cells and that is located in the prostate.

MalaCards based summary : Prostatic Adenoma, also known as prostatic hyperplasia, is related to prostatic hyperplasia, benign and impotence, and has symptoms including prostatism An important gene associated with Prostatic Adenoma is KLK3 (Kallikrein Related Peptidase 3), and among its related pathways/superpathways are Signaling by GPCR and Peptide ligand-binding receptors. The drugs Selegiline and Scopolamine have been mentioned in the context of this disorder. Affiliated tissues include prostate, testes and smooth muscle, and related phenotypes are Decreased substrate adherent cell growth and behavior/neurological

Related Diseases for Prostatic Adenoma

Diseases related to Prostatic Adenoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 319)
# Related Disease Score Top Affiliating Genes
1 prostatic hyperplasia, benign 31.1 SRD5A1 SERPINA3 KLK3
2 impotence 31.0 SRD5A1 KLK3 ADRA1D ADRA1B ADRA1A
3 prostatitis 30.9 SERPINA3 KLK3 ADRA1A
4 androgenic alopecia 30.6 SRD5A1 KLK3
5 urethral stricture 30.5 KLK3 ADRA1D
6 prostate disease 29.7 SRD5A1 SERPINA3 KLK3
7 cystitis 29.7 ADRB3 ADRB2 ADRA1D
8 sexual disorder 29.4 SERPINA3 KLK3 ADRA2C ADRA2B ADRA2A ADRA1D
9 prostatic hypertrophy 29.0 SRD5A1 SERPINA3 KLK3 ADRA2C ADRA2B ADRA2A
10 congestive heart failure 28.8 ADRB2 ADRB1 ADRA2C
11 body mass index quantitative trait locus 11 28.6 SERPINA3 ADRB3 ADRB2 ADRB1 ADRA2A
12 hypertension, essential 26.8 SERPINA3 ADRB3 ADRB2 ADRB1 ADRA2C ADRA2B
13 pain agnosia 26.7 ADRB3 ADRB2 ADRB1 ADRA2C ADRA2B ADRA2A
14 benign prostate phyllodes tumor 11.3
15 adenoma 11.2
16 pure autonomic failure 10.5
17 overgrowth syndrome 10.5
18 adenocarcinoma 10.4
19 body mass index quantitative trait locus 1 10.4
20 suppression of tumorigenicity 12 10.4
21 aging 10.3
22 pachyonychia congenita 3 10.3
23 multinucleated neurons, anhydramnios, renal dysplasia, cerebellar hypoplasia, and hydranencephaly 10.3
24 neurogenic bladder 10.3
25 b-cell lymphoma 10.3
26 alopecia 10.3
27 insulin-like growth factor i 10.3
28 hyperinsulinism 10.3
29 infant gynecomastia 10.3
30 gynecomastia 10.3
31 48,xyyy 10.2
32 pyelonephritis 10.2
33 mycobacterium tuberculosis 1 10.2
34 syncope 10.2
35 pik3ca-related overgrowth syndrome 10.2
36 ureterolithiasis 10.2 ADRA1D ADRA1A
37 alopecia, androgenetic, 1 10.2
38 proteasome-associated autoinflammatory syndrome 1 10.2
39 non-alcoholic fatty liver disease 10.2
40 urolithiasis 10.2
41 varicocele 10.2
42 liver disease 10.2
43 fatty liver disease 10.2
44 raynaud disease 10.1 ADRA2C ADRA2B
45 body mass index quantitative trait locus 9 10.1
46 body mass index quantitative trait locus 8 10.1
47 body mass index quantitative trait locus 4 10.1
48 body mass index quantitative trait locus 10 10.1
49 body mass index quantitative trait locus 7 10.1
50 body mass index quantitative trait locus 12 10.1

Graphical network of the top 20 diseases related to Prostatic Adenoma:



Diseases related to Prostatic Adenoma

Symptoms & Phenotypes for Prostatic Adenoma

UMLS symptoms related to Prostatic Adenoma:


prostatism

GenomeRNAi Phenotypes related to Prostatic Adenoma according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased substrate adherent cell growth GR00193-A-1 8.92 ADRA1A ADRA1B ADRA1D ADRA2B

MGI Mouse Phenotypes related to Prostatic Adenoma:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.96 ADRA1A ADRA1B ADRA1D ADRA2A ADRA2B ADRA2C
2 cardiovascular system MP:0005385 9.81 ADRA1A ADRA1B ADRA1D ADRA2A ADRA2B ADRA2C
3 homeostasis/metabolism MP:0005376 9.65 ADRA1A ADRA1B ADRA2A ADRA2B ADRA2C ADRB1
4 muscle MP:0005369 9.23 ADRA1A ADRA1B ADRA1D ADRA2B ADRB1 ADRB2

Drugs & Therapeutics for Prostatic Adenoma

Drugs for Prostatic Adenoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 199)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Selegiline Approved, Investigational, Vet_approved Phase 4 14611-51-9 5195 26757
2
Scopolamine Approved, Investigational Phase 4 6533-68-2, 51-34-3 5184
3
Saw palmetto Approved, Experimental, Investigational Phase 4
4
Silodosin Approved Phase 4 160970-54-7
5
Sodium citrate Approved, Investigational Phase 4 68-04-2
6
carbamide peroxide Approved Phase 4 124-43-6
7
Testosterone Approved, Experimental, Investigational Phase 4 58-22-0, 481-30-1 10204 6013
8
Testosterone enanthate Approved Phase 4 315-37-7 9416
9
Testosterone undecanoate Approved, Investigational Phase 4 5949-44-0
10
Methyltestosterone Approved Phase 4 58-18-4 6010
11
Ertapenem Approved, Investigational Phase 4 153832-46-3 150610
12
Ciprofloxacin Approved, Investigational Phase 4 85721-33-1 2764
13
Tranexamic Acid Approved Phase 4 1197-18-8 5526
14
Dihydrotachysterol Approved Phase 4 67-96-9 5311071 5281010
15
Levobupivacaine Approved, Investigational Phase 4 27262-47-1 92253
16
Rocuronium Approved Phase 4 119302-91-9, 143558-00-3 441290
17
Mivacurium Approved Phase 4 106791-40-6, 133814-19-4 5281042
18
Atracurium Approved, Experimental, Investigational Phase 4 64228-79-1 47319
19
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
20
Diclofenac Approved, Vet_approved Phase 4 15307-86-5 3033
21
Tadalafil Approved, Investigational Phase 4 171596-29-5 110635
22
Methoxyflurane Approved, Investigational, Vet_approved Phase 4 76-38-0 4116
23
Dutasteride Approved, Investigational Phase 4 164656-23-9 152945 6918296
24
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
25
Aspartic acid Approved, Nutraceutical Phase 4 56-84-8 5960
26
Cimetropium Experimental, Investigational Phase 4 150521-16-7
27 Naftopidil Investigational Phase 4 57149-07-2
28
Dihydrotestosterone Illicit, Investigational Phase 4 521-18-6 10635
29
Fibrinolysin Investigational Phase 4 9004-09-5
30 Protective Agents Phase 4
31 Anticonvulsants Phase 4
32 Bromides Phase 4
33 Cola Phase 4
34 Antiparkinson Agents Phase 4
35 Psychotropic Drugs Phase 4
36 Neuroprotective Agents Phase 4
37 Monoamine Oxidase Inhibitors Phase 4
38 Gastrointestinal Agents Phase 4
39 Antiemetics Phase 4
40 Mydriatics Phase 4
41 Butylscopolammonium Bromide Phase 4
42 Anti-Infective Agents Phase 4
43 Saw palmetto extract Phase 4
44 Cholinergic Agents Phase 4
45 Solifenacin succinate Phase 4 242478-38-2
46 Muscarinic Antagonists Phase 4
47 Cholinergic Antagonists Phase 4
48 Platelet Aggregation Inhibitors Phase 4
49 Calcium, Dietary Phase 4
50 calcium channel blockers Phase 4

Interventional clinical trials:

(show top 50) (show all 568)
# Name Status NCT ID Phase Drugs
1 Clinical Pilot Trial on the Influence of a Saw Palmetto Berry Preparation on Sexual Functions in Patients With Benign Prostatic Hyperplasia Unknown status NCT01021267 Phase 4 Saw palmetto berry extract
2 A Prospective Multicenter Randomized Study Comparing Photoselective Vaporization of the Prostate With the GreenLight XPS™ Laser System and Transurethral Resection of the Prostate for the Treatment of Benign Prostatic Hyperplasia (The Goliath Study) Unknown status NCT01218672 Phase 4
3 EFFICACY AND SAFETY OF COMBINATION THERAPY WITH β3-ADRENOCEPTOR AGONIST (MIRABEGRON) AND α-ADRENOCEPTOR ANTAGONIST (TAMSULOSIN) FOR TREATMENT OF OVERACTIVE BLADDER IN MALE PATIENTS WITH BENIGN PROSTATIC HYPERPLASIA. Unknown status NCT02279615 Phase 4 Mirabegron;Tamsulosin
4 Kinetics of the Finasteride Prostate Induced Apoptosis Unknown status NCT00130767 Phase 4 finasteride
5 Switch Study: Are There Any Measurable Differences When Switching Patients on Finasteride Therapy to Dutasteride? Unknown status NCT00690950 Phase 4 Dutasteride
6 Usefulness Of Flospan As A Premedication For Colonoscopy : A Randomized Double Blind Controlled Trial Unknown status NCT01842932 Phase 4 Phloroglucin;Cimetropium bromide;Placebo
7 Post-Marketing Study Using PROLIEVE® for the Treatment of Benign Prostatic Hyperplasia (BPH) Unknown status NCT02021032 Phase 4
8 Prospective Non-randomized Trial Comparing Holmium Laser Enucleation of the Prostate Versus Greenlight Laser Photoselective Vaporization of the Prostate in Treating Benign Prostate Hyperplasia in Patients With Bleeding Tendency Unknown status NCT02293759 Phase 4
9 Evaluation of Solifenacin in the Treatment of OAB Symptoms in Patients Who Have Successfully Undergone GreenLight Photoselective Vaporization of the Prostate (PVP)for the Treatment of Clinically Significant Benign Prostate Hyperplasia (BPH) Unknown status NCT00826527 Phase 4 Solifenacin PO
10 An Open-label Trial of Oral Selegiline 5 or 10 mg and Tadalafil 2.5mg Co-administration to Male Patients With Parkinson's Disease and Moderate Erectile Dysfunction. Unknown status NCT02225548 Phase 4 Selegiline;Tadalafil
11 Does Hyoscine N-butylbromide Administered During Colonoscopy Increase the Polyp Detection Rate? a Randomized, Single Center, Double Blind, Placebo-controlled Study Unknown status NCT01609855 Phase 4 Hyoscine Butyl Bromide 20mg/2 ml i.v.;Saline 2 ml i.v.
12 Prostatic Artery Embolization Versus 532 nm Green Light Laser Photoselective Vaporization of the Prostate for Treating Catheter-Dependent Patients With Benign Prostatic Hyperplasia: A Randomized Controlled Clinical Study Unknown status NCT02006303 Phase 4
13 Behavior and Exercise Versus Drug Treatment in Men With Nocturia Unknown status NCT00824200 Phase 4 tamsulosin (alpha-adrenergic antagonist medication);placebo
14 Comparation the Effect of C-LMA and I-gel in Regurgitation and Postoperative Complications Unknown status NCT01876836 Phase 4
15 Low Dose, Low Concentration Different Baricity Bupivacaine for Transuretral Prostatectomy. Unknown status NCT01861041 Phase 4 Heavy Bupivacaine;Isobaric Bupivacaine
16 A Multicenter, Randomized, Double-blind, Clinical Study to Investigate the Efficacy and Safety of Treatment With Tamsulosin 0.2mg Mono and Tamsulosin 0.2mg, Finasteride 5mg Combination Therapy in Patients With LUTS/BPH Unknown status NCT01736033 Phase 4 Tamsulosin;Finasteride;Placebo
17 Ejaculatory Sparing vs. Non-ejaculatory Sparing GreenLightTM Laser Photoselective Vaporization of the Prostate (PVP): A Randomized Double Blind Sexual and Urodynamic Assessment Unknown status NCT02749604 Phase 4
18 The Effect of KTP (Potassium-titanyl-phosphate) Green Light Prostatectomy (180W) Compared With Open Prostatectomy When Treating Benign Prostatic Hyperplasia, a Prospective Randomized Study Completed NCT02072499 Phase 4
19 Comparison Between Alpha Blocker Monotherapy and 5-alpha-reductase Inhibitor Monotherapy Following Combination Therapy in Benign Prostatic Hyperplasia Completed NCT01301599 Phase 4 combination therapy;alpha blocker monotherapy;5 alpha reductase inhibitor monotherapy
20 A 12-week, Open Label, Multi-center Study to Investigate the Efficacy and Safety of a α1A Adrenoceptor Selective Antagonist Silodosin on Urinary Disturbance Associated With Benign Prostatic Hyperplasia Completed NCT01259531 Phase 4 Silodosin
21 Efficacy and Safety of Naftopidil in Patient With Neurogenic Lower Urinary Tract Dysfunction Not Caused by Benign Prostatic Hyperplasia Completed NCT02034604 Phase 4 Naftofidil;Tamsulosin
22 A Randomized, Double-blind, Placebo-controlled Study to Assess the Effect of Tamsulosin OCAS 0.4 mg Tablets, Once Daily on Nocturia, Compared to Placebo, in Patients With Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia Completed NCT00379067 Phase 4 Tamsulosin OCAS;Placebo
23 An Open-Label Randomized Phase 4 Study of Greenlight XPS Laser Versus BiVAP Saline Vaporization of the Prostate in Men With Symptomatic Benign Prostatic Hyperplasia Completed NCT01500057 Phase 4
24 PERMIXON® 160 mg Hard Capsule Versus Placebo in the Treatment of Symptomatic Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia Completed NCT02121613 Phase 4 Permixon® 160 mg;Tamsulosine LP;Placebo matching Permixon® 160 mg;Placebo matching Tamsulosine LP
25 Evaluation of the Effect of 10 mg Alfuzosin (Alfetim Uno®) o. d. in Patients Presenting Low-Urinary Tract Symptoms Completed NCT00637715 Phase 4 Alfuzosin
26 A Forty-Five Day, Open-label Study of the Symptomatic Relief Effects of FLOMAX® Capsules 0.4 mg Daily in Patients With the Signs and Symptoms of Benign Prostatic Hyperplasia Completed NCT02244242 Phase 4 Tamsulosin hydrochloride
27 Study of the Outcome of Patients With Lower Urinary Symptoms Suggestive of Benign Prostatic Hyperplasia and Treated With Alfuzosin 10 mg Once Daily for 3 Months in China Completed NCT00280605 Phase 4 Alfuzosin
28 An Eleven-Week, Open-Label, Randomized, Multicenter, Parallel-Design, Placebo Lead-in Study of FLOMAX® Capsules, 0.4 mg Daily Versus HYTRIN® Capsules, 5 mg (With Titration) Daily in Patients With the Signs and Symptoms of Benign Prostatic Hyperplasia Completed NCT02244255 Phase 4 FLOMAX® capsules;Ascending doses of HYTRIN® capsules
29 A Post-Marketing Clinical Study of LY450190 (Combined With Alpha1 Blocker Treatment) Completed NCT02431754 Phase 4 Tadalafil;Placebo;Alpha1 Blocker
30 A Randomized, Double-blind, Double-dummy, Placebo-controlled, Parallel Design Clinical Trial to Evaluate the Efficacy and Safety of Naftopidil in Male Patients With Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia Completed NCT01922375 Phase 4 Naftopidil
31 Evaluation of the Effects of Monopolar Transurethral Resection Versus Bipolar Transurethral Resection and Holmium Laser Enucleation of the Prostate on Urinary and Sexual Function; a Prospective Comparative Study. Completed NCT01810068 Phase 4
32 Green Light Laser (XPS) Photoselective Vaporization of the Prostate (PVP) Versus Bipolar Transurethral Vaporization (B.TUVP) of the Prostate for Treatment of Small to Moderate Sized Benign Prostate Hyperplasia: A Randomized Study Completed NCT02283684 Phase 4
33 Efficacy of Silodosin in the Treatment of Symptomatic Benign Prostatic Hyperplasia (BPH) Completed NCT04107896 Phase 4 Silodosin;Tamsulosin
34 Sexuality And Management of Benign Prostatic Hyperplasia With Alfuzosin 10mg Once Daily (XATRAL 10mg OD), Open, 24-week Study. Completed NCT00401661 Phase 4 Alfuzosin
35 Apoptosis and Expression of Neovascularization-related Factors in Human Prostate Tissue After Administration of Dutasteride Completed NCT00880672 Phase 4 dutasteride
36 BLADDER (BPH, LUTS And Detrusor: Dual Effect Research) Study: A Multicentre, Double-blind, Randomised, Parallel Group, Placebo-controlled Study, Aimed at Characterising the Effect of Tamsulosin on Lower Urinary Tract Symptoms (LUTS) and Detrusor Motor Activity in Patients Affected by Benign Prostatic Hyperplasia (BPH) and Storage Urinary Symptoms Completed NCT02245490 Phase 4 Tamsulosin HCl controlled release capsules;Matching placebo capsule
37 Effectiveness and Safety of Silodosin in the Treatment of LUTS in Patients With Benign Prostatic Hyperplasia: a European Phase IV Clinical Study. The Silodosin in Real-life Evaluation Study Completed NCT01757769 Phase 4 Silodosin
38 A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study of Solifenacin Succinate as Add-on Therapy for Overactive Bladder (OAB) Symptoms in Men Treated for Benign Prostatic Hyperplasia (BPH) With Tamsulosin Hydrochloride Completed NCT00771394 Phase 4 Tamsulosin hydrochloride;Solifenacin succinate
39 An Open-label, Prospective Interventional Study of the Tolerability and Efficacy of Oral Harnalidge® OCAS® (Tamsulosin) 0.4 mg in Patients Who Are Unsatisfied With the Treatment of Tamsulosin 0.2 mg Completed NCT02180789 Phase 4 Tamsulosin OCAS
40 A Randomized, Open-label, Parallel-group Study, to Assess the Pharmocodynamic Effect on Dihydrotestosterone Regulated Gene Expression, Longitudinally and in a Dose Dependent Manner, of 0.5mg and 3.5mg Dutasteride Administered Orally Once Daily, for One Year in Men With Symptomatic Benign Prostatic Hyperplasia and During a Two Month Period Between Baseline and Radical Prostatectomy in Men With Biopsy-proven, Clinically Localized Prostate Cancer Completed NCT00375765 Phase 4 Dutasteride
41 A Multi-center, Prospective, Open-label, Single-arm, 12-weeks, Phase IV Trial to Evaluate the Efficacy and Safety of Silodosin on Nocturia for Patients With Benign Prostatic Hyperplasia Completed NCT02106182 Phase 4 Silodosin
42 ALEX-XL: Alfuzosin XL-Lower Urinary Tract Symptoms Efficacy and Sexuality Study Completed NCT00575913 Phase 4 Alfuzosin
43 A Prospective Clinical Study for GreenLight HPS in the Treatment of Obstructive Benign Prostatic Hyperplasia (BPH) Completed NCT00465101 Phase 4
44 A Phase 4, Double-blind, Randomized, Placebo-controlled Multicenter Study to Evaluate the Efficacy and Safety of Mirabegron in Japanese and Korean Male Patients With Overactive Bladder Under Treatment With the α-Blocker Tamsulosin for Benign Prostatic Hyperplasia Completed NCT02656173 Phase 4 Mirabegron;Placebo;Tamsulosin
45 A Multicenter, Randomized, Parallel Group, Double-Blind, Placebo-Controlled Flexible Dose Study With and Open-Label Extension to Assess the Efficacy and Safety of Viagra (Sildenafil Citrate) in the Treatment of Men With Erectile Dysfunction (ED) and Concomitant Lower Urinary Tract Symptoms (LUTS) Associated With Benign Prostatic Hyperplasia (BPH) in the United States Completed NCT00143221 Phase 4 Viagra;Placebo
46 A Prospective Evaluation of the GreenLight Model 120 Laser System for the Treatment of Benign Prostatic Hyperplasia Completed NCT00364585 Phase 4
47 Dutasteride (0.5mg) Once Daily for One Year and Tamsulosin (0.4mg) Once Daily for 3 Months, Followed by Counseling on Flex Dose Tamsulosin as Needed on Improvement of Symptoms and Outcome in Men With Moderate to Severe Symptomatic BPH Completed NCT00701779 Phase 4 Tamsulosin
48 MICTUS (Multicentre Investigation to Characterise the Effect of Tamsulosin on Urinary Symptoms): A Multicentre, Double-blind, Randomised, Parallel Group Study, Aimed at Characterising the Effect of Tamsulosin, an Uroselective α1- Receptor Blocking Agent, on the Urological Symptoms and Their Impact on General Health Status and Quality of Life in Outpatients Affected by Symptomatic Benign Prostatic Hyperplasia: Comparison With Finasteride. Completed NCT02244229 Phase 4 Tamsulosin;Finasteride;Placebo
49 Sexuality And Management of Benign Prostatic Hyperplasia With Alfuzosin 10mg Once Daily (XATRAL OD 10mg), Open, 24-week Study Completed NCT00486785 Phase 4 Alfuzosin
50 The Long Term Effects of Alfuzosin (Xatral XL) in LUTS/BPH Patients: Evaluation of Symptom-specific Goal Achievement According to Symptom Improvement, Bladder Outlet Obstruction Grade and Bladder Contractility Completed NCT00836823 Phase 4 Alfuzosin

Search NIH Clinical Center for Prostatic Adenoma

Inferred drug relations via UMLS 71 / NDF-RT 50 :


alfuzosin
Doxazosin
Doxazosin Mesylate
Dutasteride
Finasteride
Leuprolide
Leuprolide Acetate
Prazosin
Prazosin hydrochloride
Saw palmetto extract
silodosin
tamsulosin
Tamsulosin hydrochloride
Terazosin
terazosin hydrochloride

Cochrane evidence based reviews: prostatic hyperplasia

Genetic Tests for Prostatic Adenoma

Anatomical Context for Prostatic Adenoma

The Foundational Model of Anatomy Ontology organs/tissues related to Prostatic Adenoma:

19
Prostate

MalaCards organs/tissues related to Prostatic Adenoma:

40
Prostate, Testes, Smooth Muscle, Bone, Endothelial, Kidney, Liver

Publications for Prostatic Adenoma

Articles related to Prostatic Adenoma:

(show top 50) (show all 14788)
# Title Authors PMID Year
1
[Efficacy and safety of combined treatment of prostatic adenoma with 5-alpha reductase and alpha-adrenoblockers]. 54 61
20169718 2009
2
[The experience in dutasteride use before transurethral prostatic resection for large adenoma]. 61 54
19054996 2008
3
[Dutasteride--an inhibitor of 5alpha-reductase of type I and II--in the treatment of patients with prostatic adenoma. What is the latest news?]. 54 61
18652016 2007
4
[Treatment of prostatic adenoma patients with inhibitor of 5-alpha-reductase of type I and II avodart (dutasteride)]. 54 61
17315721 2006
5
Impact of prostate-specific antigen level and prostate volume as predictors of efficacy in photoselective vaporization prostatectomy: analysis and results of an ongoing prospective multicentre study at 3 years. 61 54
16686717 2006
6
[Proscar (finasteride, MSD) in the treatment of patients with prostatic hyperplasia]. 54 61
8928344 1996
7
Effect of digital rectal examination on plasma prostate-specific antigen (PSA). 61 54
8836791 1996
8
The efficacy of finasteride in the treatment of symptomatic benign prostatic hyperplasia. 54 61
8851481 1995
9
Relationship between prostate-specific antigen, prostate volume, retention volume and age in benign prostatic hypertrophy (BPH). 54 61
8725044 1995
10
Predicted and actual change in serum PSA following prostatectomy for BPH. 54 61
7512298 1994
11
[Effect of rectal examination in patients with prostatic adenoma on concentration of prostatic specific antigen (PSA) in plasma]. 61 54
7526558 1993
12
Experience with prostate-specific antigen in prostatic carcinoma. 61 54
1718923 1991
13
[5-alpha reductase inhibitor in prostatic adenoma?]. 61 54
1705307 1990
14
Inhibition of neurogenic and thromboxane A2 -induced human prostate smooth muscle contraction by the integrin α2β1 inhibitor BTT-3033 and the integrin-linked kinase inhibitor Cpd22. 61
32449814 2020
15
Urethral luminal epithelia are castration-insensitive cells of the proximal prostate. 61
32497356 2020
16
Health Risks Associated with Long-Term Finasteride and Dutasteride Use: It's Time to Sound the Alarm. 61
32202088 2020
17
Clinical Comparison of Holmium Laser Enucleation of the Prostate and Bipolar Transurethral Enucleation of the Prostate in Patients Under Either Anticoagulation or Antiplatelet Therapy. 61
30872124 2020
18
Should All Men with Type 2 Diabetes Be Routinely Prescribed a Phosphodiesterase Type 5 Inhibitor? 61
32378365 2020
19
While Urine and Plasma Decorin Remain Unchanged in Prostate Cancer, Prostatic Tissue Decorin Has a Prognostic Value. 61
32306717 2020
20
Transurethral endoscopic enucleation of the prostate using a diode laser versus bipolar plasmakinetic for benign prostatic obstruction: a meta-analysis. 61
31919682 2020
21
Botulinum toxin in low urinary tract disorders - over 30 years of practice (Review). 61
32509003 2020
22
Prostate MR: pitfalls and benign lesions. 61
31705249 2020
23
Modulatory Effect of Silymarin on Apoptosis in Testosterone -Induced Benign Prostatic Hyperplasia in Rats. 61
31902118 2020
24
Evaluation of Clinical Outcomes of Prostatic Urethral Lift for Benign Prostatic Hyperplasia: An Asian Population Study. 61
31385478 2020
25
Benign prostatic hyperplasia treatment using plasmonic nanoparticles irradiated by laser in a rat model. 61
32244195 2020
26
Re: Water Vapor Thermal Therapy to Alleviate Catheter-Dependent Urinary Retention Secondary to Benign Prostatic Hyperplasia. 61
32272052 2020
27
Peanut Sprout Extracts Cultivated with Fermented Sawdust Medium Inhibits Benign Prostatic Hyperplasia In Vitro and In Vivo. 61
32202087 2020
28
Use of 70- to 150-μm Radiopaque Spherical Embolics for Prostatic Artery Embolization. 61
32457008 2020
29
Prostate sarcomas: A radiological mimic for benign prostatic hyperplasia. 61
32300534 2020
30
Prostatic osteopontin expression is associated with symptomatic benign prostatic hyperplasia. 61
32356572 2020
31
Effects of vibegron, a novel β3-adrenoceptor agonist, and its combination with imidafenacin or silodosin in a rat with partial bladder outlet obstruction. 61
32259514 2020
32
High Detection Rate for Non-Muscle-Invasive Bladder Cancer Using an Approved DNA Methylation Signature Test. 61
32139301 2020
33
The recurrence and progression risk after simultaneous endoscopic surgery of urothelial bladder tumor and benign prostatic hyperplasia; a systematic review and meta-analysis. 61
32564458 2020
34
ARHGEF38 as a novel biomarker to predict aggressive prostate cancer. 61
32215291 2020
35
AST/ALT ratio as a significant predictor of the incidence risk of prostate cancer. 61
32562455 2020
36
Ethanol-extracted Cameroonian propolis: Antiproliferative effects and potential mechanism of action in prostate cancer. 61
32573810 2020
37
Characterization of N-linked intact glycopeptide signatures of plasma IgGs from patients with prostate carcinoma and benign prostatic hyperplasia for diagnosis pre-stratification. 61
32568312 2020
38
Prostate volume and age are predictors of energy delivery using the CoreTherm Concept in patients with LUTS/BPO: a study on thermal dose. 61
32401123 2020
39
Association of KLK3, VAMP8 and MDM4 Genetic Variants within microRNA Binding Sites with Prostate Cancer: Evidence from Serbian Population. 61
32556890 2020
40
Anatomical endoscopic enucleation of the prostate: The next gold standard? No! (or not yet!). 61
32559344 2020
41
Surgical training for anatomical endoscopic enucleation of the prostate. 61
32557751 2020
42
To examine serum paraoxonase 1 and 3 activities in benign and malignant diseases of the prostate, and changes in levels following robotic-assisted laparoscopic radical prostatectomy. 61
32549522 2020
43
Daily salt intake is associated with leg edema and nocturnal urinary volume in elderly men. 61
32460398 2020
44
Early patient experience following treatment with the UroLift prostatic urethral lift and Rezum steam injection. 61
32544043 2020
45
Reviewing the Evidence on Vitamin D Supplementation in the Management of Testosterone Status and Its Effects on Male Reproductive System (Testis and Prostate): Mechanistically Dazzling but Clinically Disappointing. 61
32446600 2020
46
Immunohistochemical expression of Cyclin D1 among Sudanese patients diagnosed with benign and malignant prostatic lesions. 61
32552908 2020
47
Evaluation of the plasma level of long non-coding RNA PCAT1 in prostatic hyperplasia and newly diagnosed prostate cancer patients. 61
32529802 2020
48
The metabolic role of PFKFB4 in androgen-independent growth in vitro and PFKFB4 expression in human prostate cancer tissue. 61
32487245 2020
49
Promotion of epithelial hyperplasia by interleukin-8-CXCR axis in human prostate. 61
32542667 2020
50
The protective effect of Sophora japonica on prostatic hypertrophy and inflammation in rat. 61
32504221 2020

Variations for Prostatic Adenoma

Expression for Prostatic Adenoma

Search GEO for disease gene expression data for Prostatic Adenoma.

Pathways for Prostatic Adenoma

Pathways related to Prostatic Adenoma according to GeneCards Suite gene sharing:

(show all 20)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.96 KLK3 CLIP3 ADRB3 ADRB2 ADRB1 ADRA2C
2
Show member pathways
13.41 ADRB3 ADRB2 ADRB1 ADRA2C ADRA2B ADRA2A
3
Show member pathways
13.36 NUDT6 ADRB3 ADRB2 ADRB1 ADRA2C ADRA2B
4
Show member pathways
12.71 ADRB2 ADRB1 ADRA2B ADRA2A ADRA1B ADRA1A
5
Show member pathways
12.4 ADRB3 ADRB2 ADRB1 ADRA1D ADRA1B ADRA1A
6
Show member pathways
12.36 ADRB2 ADRA2C ADRA2B ADRA2A
7
Show member pathways
12.31 ADRB3 ADRB2 ADRB1 ADRA2C ADRA2B ADRA2A
8
Show member pathways
12.15 ADRB3 ADRB2 ADRB1 ADRA1D ADRA1B ADRA1A
9
Show member pathways
12.09 ADRB3 ADRB2 ADRB1
10
Show member pathways
12.03 ADRA2C ADRA2B ADRA2A ADRA1D ADRA1B ADRA1A
11
Show member pathways
11.96 ADRB3 ADRB2 ADRB1 ADRA1D ADRA1B ADRA1A
12 11.92 ADRB3 ADRB2 ADRB1
13
Show member pathways
11.83 ADRA1D ADRA1B ADRA1A
14
Show member pathways
11.71 ADRA2C ADRA2B ADRA2A
15 11.55 ADRB3 ADRB2 ADRB1
16 11.51 ADRB2 ADRB1 ADRA2A ADRA1D
17 11.43 ADRB3 ADRB2 ADRB1
18
Show member pathways
11.32 ADRB3 ADRB2 ADRB1 ADRA2C ADRA2B ADRA2A
19 11.12 ADRB1 ADRA1A
20 10.92 ADRB2 ADRB1 ADRA2C ADRA2B ADRA2A ADRA1D

GO Terms for Prostatic Adenoma

Cellular components related to Prostatic Adenoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 plasma membrane GO:0005886 9.65 CLIP3 ADRB3 ADRB2 ADRB1 ADRA2C ADRA2B
2 integral component of plasma membrane GO:0005887 9.28 ADRB3 ADRB2 ADRB1 ADRA2C ADRA2B ADRA2A

Biological processes related to Prostatic Adenoma according to GeneCards Suite gene sharing:

(show all 35)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.22 TAFA4 NUDT6 ADRB3 ADRB2 ADRB1 ADRA2C
2 G protein-coupled receptor signaling pathway GO:0007186 10.18 ADRB3 ADRB2 ADRB1 ADRA2C ADRA2B ADRA2A
3 cell-cell signaling GO:0007267 9.97 ADRB3 ADRB2 ADRB1 ADRA2C ADRA2B ADRA2A
4 adenylate cyclase-activating G protein-coupled receptor signaling pathway GO:0007189 9.88 ADRB3 ADRB2 ADRB1 ADRA2A
5 positive regulation of MAPK cascade GO:0043410 9.86 ADRB3 ADRB2 ADRA2C ADRA2B ADRA2A ADRA1D
6 positive regulation of vasoconstriction GO:0045907 9.85 ADRA2C ADRA1D ADRA1B ADRA1A
7 positive regulation of cytosolic calcium ion concentration GO:0007204 9.83 ADRA1D ADRA1B ADRA1A
8 platelet activation GO:0030168 9.81 ADRA2C ADRA2B ADRA2A
9 positive regulation of cold-induced thermogenesis GO:0120162 9.81 ADRB3 ADRB2 ADRB1
10 regulation of vasoconstriction GO:0019229 9.8 ADRA2C ADRA2B ADRA2A ADRA1B ADRA1A
11 phospholipase C-activating G protein-coupled receptor signaling pathway GO:0007200 9.79 ADRA1D ADRA1B ADRA1A
12 activation of adenylate cyclase activity GO:0007190 9.79 ADRB3 ADRB2 ADRB1
13 activation of protein kinase B activity GO:0032148 9.77 ADRA2C ADRA2B ADRA2A
14 adrenergic receptor signaling pathway GO:0071875 9.76 ADRB3 ADRB2 ADRA2C ADRA2B ADRA2A ADRA1D
15 positive regulation of smooth muscle contraction GO:0045987 9.74 ADRA1D ADRA1B ADRA1A
16 negative regulation of norepinephrine secretion GO:0010700 9.73 ADRA2C ADRA2B ADRA2A
17 regulation of smooth muscle contraction GO:0006940 9.73 ADRB2 ADRA2C ADRA2B ADRA2A
18 receptor transactivation GO:0035624 9.71 ADRA2C ADRA2B ADRA2A
19 negative regulation of epinephrine secretion GO:0032811 9.69 ADRA2C ADRA2B ADRA2A
20 response to cold GO:0009409 9.67 ADRB2 ADRB1
21 norepinephrine-epinephrine vasoconstriction involved in regulation of systemic arterial blood pressure GO:0001994 9.67 ADRA1D ADRA1B ADRA1A
22 positive regulation of heart rate by epinephrine-norepinephrine GO:0001996 9.67 ADRB1 ADRA1D ADRA1B ADRA1A
23 regulation of sensory perception of pain GO:0051930 9.66 TAFA4 ADRA2C
24 brown fat cell differentiation GO:0050873 9.66 ADRB2 ADRB1
25 temperature homeostasis GO:0001659 9.65 ADRB3 ADRB1
26 regulation of cardiac muscle contraction GO:0055117 9.65 ADRA1B ADRA1A
27 regulation of muscle contraction GO:0006937 9.64 ADRA1B ADRA1A
28 negative regulation of multicellular organism growth GO:0040015 9.63 ADRB2 ADRB1
29 norepinephrine-epinephrine-mediated vasodilation involved in regulation of systemic arterial blood pressure GO:0002025 9.63 ADRB3 ADRB2 ADRB1
30 diet induced thermogenesis GO:0002024 9.62 ADRB2 ADRB1
31 desensitization of G protein-coupled receptor signaling pathway by arrestin GO:0002032 9.61 ADRB3 ADRB2
32 adenylate cyclase-activating adrenergic receptor signaling pathway GO:0071880 9.61 ADRB3 ADRB2 ADRB1 ADRA2C ADRA2B ADRA2A
33 heat generation GO:0031649 9.59 ADRB2 ADRB1
34 positive regulation of the force of heart contraction by epinephrine-norepinephrine GO:0001997 9.58 ADRB1 ADRA1A
35 adenylate cyclase-modulating G protein-coupled receptor signaling pathway GO:0007188 9.28 ADRB3 ADRB2 ADRB1 ADRA2C ADRA2B ADRA2A

Molecular functions related to Prostatic Adenoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 G protein-coupled receptor activity GO:0004930 9.91 ADRB3 ADRB2 ADRB1 ADRA2C ADRA2B ADRA2A
2 protein heterodimerization activity GO:0046982 9.8 ADRB1 ADRA2C ADRA2A ADRA1B ADRA1A
3 alpha2-adrenergic receptor activity GO:0004938 9.54 ADRA2C ADRA2B ADRA2A
4 alpha1-adrenergic receptor activity GO:0004937 9.5 ADRA1D ADRA1B ADRA1A
5 alpha-2A adrenergic receptor binding GO:0031694 9.46 ADRB1 ADRA2C
6 norepinephrine binding GO:0051380 9.46 ADRB3 ADRB2 ADRB1 ADRA2A
7 beta-adrenergic receptor activity GO:0004939 9.43 ADRB3 ADRB1
8 epinephrine binding GO:0051379 9.43 ADRB3 ADRB2 ADRB1 ADRA2C ADRA2B ADRA2A
9 adrenergic receptor activity GO:0004935 9.28 ADRB3 ADRB2 ADRB1 ADRA2C ADRA2B ADRA2A

Sources for Prostatic Adenoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....